• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脊髓性肌萎缩症的诊断和管理:第 1 部分:诊断、康复、矫形和营养护理建议。

Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care.

机构信息

Paediatric Neurology Unit, Catholic University, Rome, Italy; Centro Clinico Nemo, Policlinico Gemelli, Rome, Italy.

Nemours Children's Hospital, University of Central Florida College of Medicine, Orlando, FL, USA.

出版信息

Neuromuscul Disord. 2018 Feb;28(2):103-115. doi: 10.1016/j.nmd.2017.11.005. Epub 2017 Nov 23.

DOI:10.1016/j.nmd.2017.11.005
PMID:29290580
Abstract

Spinal muscular atrophy (SMA) is a severe neuromuscular disorder due to a defect in the survival motor neuron 1 (SMN1) gene. Its incidence is approximately 1 in 11,000 live births. In 2007, an International Conference on the Standard of Care for SMA published a consensus statement on SMA standard of care that has been widely used throughout the world. Here we report a two-part update of the topics covered in the previous recommendations. In part 1 we present the methods used to achieve these recommendations, and an update on diagnosis, rehabilitation, orthopedic and spinal management; and nutritional, swallowing and gastrointestinal management. Pulmonary management, acute care, other organ involvement, ethical issues, medications, and the impact of new treatments for SMA are discussed in part 2.

摘要

脊髓性肌萎缩症(SMA)是一种严重的神经肌肉疾病,由生存运动神经元 1 (SMN1)基因缺陷引起。其发病率约为每 11000 例活产儿中有 1 例。2007 年,国际 SMA 护理标准会议发表了 SMA 护理标准的共识声明,该声明已在全球范围内广泛使用。在这里,我们报告了对上一次推荐主题的两部分更新。在第 1 部分中,我们介绍了实现这些建议的方法,并更新了诊断、康复、矫形和脊柱管理;以及营养、吞咽和胃肠道管理。第 2 部分讨论了肺部管理、急性护理、其他器官受累、伦理问题、药物治疗以及 SMA 新疗法的影响。

相似文献

1
Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care.脊髓性肌萎缩症的诊断和管理:第 1 部分:诊断、康复、矫形和营养护理建议。
Neuromuscul Disord. 2018 Feb;28(2):103-115. doi: 10.1016/j.nmd.2017.11.005. Epub 2017 Nov 23.
2
Recommendations for the diagnosis and management of typical childhood spinal muscular atrophy.儿童脊髓性肌萎缩症的诊断和管理建议。
Rev Neurol (Paris). 2012 Dec;168(12):902-9. doi: 10.1016/j.neurol.2012.07.020. Epub 2012 Oct 26.
3
Augmenting the SMN Protein to Treat Infantile Spinal Muscular Atrophy.增强 SMN 蛋白治疗婴儿型脊髓性肌萎缩症。
Neuron. 2018 Mar 7;97(5):1001-1003. doi: 10.1016/j.neuron.2018.02.009.
4
Infantile spinal muscular atrophy (SMA).婴儿脊髓性肌萎缩症(SMA)。
Arch Pediatr. 2020 Dec;27(7S):7S1-7S2. doi: 10.1016/S0929-693X(20)30268-2.
5
Functional and surgical treatments in patients with spinal muscular atrophy (SMA).脊髓性肌萎缩症(SMA)患者的功能和手术治疗。
Arch Pediatr. 2020 Dec;27(7S):7S35-7S39. doi: 10.1016/S0929-693X(20)30275-X.
6
[Identification of T274I mutation in the SMN1 gene in a patient with spinal muscular atrophy].[脊髓性肌萎缩症患者SMN1基因T274I突变的鉴定]
Med Wieku Rozwoj. 2002 Oct-Dec;6(4):319-27.
7
Descriptive epidemiology of spinal muscular atrophy type I in Estonia.爱沙尼亚I型脊髓性肌萎缩症的描述性流行病学
Neuroepidemiology. 2006;27(3):164-8. doi: 10.1159/000096128.
8
Childhood spinal muscular atrophy: controversies and challenges.儿童脊髓性肌萎缩症:争议与挑战。
Lancet Neurol. 2012 May;11(5):443-52. doi: 10.1016/S1474-4422(12)70061-3.
9
Clinical features of spinal muscular atrophy (SMA) type 2.脊髓性肌萎缩症(SMA)2 型的临床特征。
Arch Pediatr. 2020 Dec;27(7S):7S18-7S22. doi: 10.1016/S0929-693X(20)30272-4.
10
Two Japanese Patients With SMA Type 1 Suggest that Axonal-SMN May Not Modify the Disease Severity.两名患有1型脊髓性肌萎缩症的日本患者表明,轴突性生存运动神经元蛋白可能不会改变疾病严重程度。
Pediatr Neurol. 2015 Jun;52(6):638-41. doi: 10.1016/j.pediatrneurol.2015.02.023. Epub 2015 Feb 28.

引用本文的文献

1
The effect of thoracolumbosacral orthosis on scoliosis progression and chest deformity in children with type 1 spinal muscular atrophy: A randomized controlled trial.胸腰骶矫形器对1型脊髓性肌萎缩症患儿脊柱侧弯进展及胸廓畸形的影响:一项随机对照试验。
PLoS One. 2025 Sep 15;20(9):e0323341. doi: 10.1371/journal.pone.0323341. eCollection 2025.
2
Antenatal Ultrasound Findings in Spinal Muscular Atrophy Type 0.0型脊髓性肌萎缩症的产前超声检查结果
Mol Genet Genomic Med. 2025 Sep;13(9):e70128. doi: 10.1002/mgg3.70128.
3
Respiratory function in 192 adult patients with spinal muscular atrophy (SMA) treated with nusinersen - a multicenter observational study.
192例接受诺西那生治疗的脊髓性肌萎缩症(SMA)成年患者的呼吸功能——一项多中心观察性研究。
Orphanet J Rare Dis. 2025 Sep 8;20(1):476. doi: 10.1186/s13023-025-04009-3.
4
Managing Spinal Muscular Atrophy: A Look at the Biology and Treatment Strategies.脊髓性肌萎缩症的管理:生物学及治疗策略概述
Biology (Basel). 2025 Aug 1;14(8):977. doi: 10.3390/biology14080977.
5
Single Nucleotide Variants in a Cohort of Individuals With Spinal Muscular Atrophy.脊髓性肌萎缩症患者队列中的单核苷酸变异
Neurol Genet. 2025 Aug 27;11(5):e200286. doi: 10.1212/NXG.0000000000200286. eCollection 2025 Oct.
6
Comorbidities in spinal muscular atrophy and their impact on the course of the underlying disease: a real-life observational study.脊髓性肌萎缩症的合并症及其对基础疾病病程的影响:一项真实世界观察性研究
BMC Musculoskelet Disord. 2025 Sep 2;26(1):839. doi: 10.1186/s12891-025-09133-6.
7
Advancing personalized spinal muscular atrophy care: matching the right biomarker to the right patient at the right time.推进个性化脊髓性肌萎缩症护理:在正确的时间为正确的患者匹配正确的生物标志物。
J Neurol. 2025 Sep 2;272(9):605. doi: 10.1007/s00415-025-13314-7.
8
Lumbar punctures based on computerized tomography scans combined with precise calculations: a new lumbar puncture technique for spinal muscular atrophy patients with scoliosis.基于计算机断层扫描并结合精确计算的腰椎穿刺:一种用于脊柱侧弯的脊髓性肌萎缩症患者的新型腰椎穿刺技术。
Front Neurol. 2025 Aug 13;16:1654310. doi: 10.3389/fneur.2025.1654310. eCollection 2025.
9
Combination therapies in spinal muscular atrophy: a systematic review.脊髓性肌萎缩症的联合疗法:一项系统评价
Eur J Pediatr. 2025 Aug 29;184(9):583. doi: 10.1007/s00431-025-06386-0.
10
Transforming Spinal Muscular Atrophy: From Pivotal Trials to Real-World Evidence and Future Therapeutic Frontiers in Types 1 and 2.转化型脊髓性肌萎缩症:从关键试验到1型和2型的真实世界证据及未来治疗前沿
Biomedicines. 2025 Aug 8;13(8):1939. doi: 10.3390/biomedicines13081939.